Key Takeaways
- Dr. David M. Reese, Amgen’s Executive Vice President and Chief Technology Officer, will retire effective June 30, 2026, after more than two decades of leadership in R&D and technology adoption.
- James Bradner, M.D., a physician‑scientist with deep expertise at the biology‑technology interface, will become Executive Vice President, Research and Development, Artificial Intelligence and Data, overseeing the convergent‑innovation agenda.
- Sean Bruich, a veteran technology and data‑science leader, is appointed Senior Vice President and Chief Technology Officer, tasked with scaling Amgen’s AI and data capabilities enterprise‑wide.
- Murdo Gordon will lead the newly created role of Executive Vice President, Amgen Global Markets and Policy, integrating Medical, Commercial Operations, Government Affairs and Policy to accelerate technology‑enabled patient access.
- Paul Burton, M.D., Ph.D., remains Senior Vice President and Chief Medical Officer, continuing his focus on delivering breakthrough therapies for cardiovascular, rare disease and obesity indications.
- The leadership shifts are designed to deepen the integration of biology, data science and advanced technologies—what Amgen terms “convergent innovation”—to accelerate drug discovery and improve patient engagement.
- Amgen reiterates its long‑standing commitment to innovation, noting its status as a Dow Jones Industrial Average component and a Nasdaq‑100 member, and outlines standard forward‑looking‑statement disclosures regarding risks and uncertainties.
Leadership Transition: Dr. David M. Reese’s Retirement
Amgen announced that Dr. David M. Reese, who has served as Executive Vice President and Chief Technology Officer since 2023, will retire effective June 30, 2026. Reese joined the company in 2005 as a clinical development leader in oncology and later headed Research and Development from 2018 to 2023, overseeing numerous drug approvals, biosimilar launches and a robust pipeline. As the inaugural CTO, he championed early adoption of artificial intelligence and data‑driven approaches across the organization, laying the groundwork for Amgen’s convergent‑innovation strategy. His departure marks the end of a era in which technology became a core pillar of Amgen’s R&D engine.
James Bradner, M.D., Takes Helm of R&D, AI and Data
To succeed Reese in the technology‑focused R&D mandate, Amgen appointed James Bradner, M.D., as Executive Vice President, Research and Development, Artificial Intelligence and Data. Bradner is a physician‑scientist recognized for bridging biology with cutting‑edge computational methods; his prior work demonstrated how machine learning can accelerate target identification and therapeutic design. In this new role, he will direct the integration of AI, data science and experimental biology to speed the discovery of novel medicines while ensuring that technological advances are tightly coupled with biological insight.
Sean Bruich Named Chief Technology Officer
Amgen also announced the appointment of Sean Bruich as Senior Vice President and Chief Technology Officer. Bruich brings a distinguished career leading global insights and AI organizations through periods of industry transformation. His expertise lies in building scalable data platforms, fostering cross‑functional analytics teams, and translating technological capabilities into measurable business outcomes. As CTO, Bruich will oversee the enterprise‑wide deployment of AI tools, cloud infrastructure and data governance, ensuring that Amgen’s technology investments deliver tangible value across R&D, manufacturing and commercial functions.
Murdo Gordon Leads Global Markets and Policy
In a move to tightly align commercial strategy with technological enablement, Murdo Gordon will assume the role of Executive Vice President, Amgen Global Markets and Policy. This expanded position consolidates Medical Affairs, Commercial Operations, Government Affairs and Policy under a single leader. Gordon’s background in global market development and policy engagement equips him to forge stronger partnerships with health systems, clinicians and payers, facilitating the adoption of advanced therapeutics and digital health solutions. His leadership aims to improve patient access to Amgen’s innovations by aligning market incentives with emerging technology trends.
Continuity at the Chief Medical Officer Role
Amgen confirmed that Paul Burton, M.D., Ph.D., will continue serving as Senior Vice President and Chief Medical Officer. Burton has been a steadfast advocate for translating scientific breakthroughs into patient‑centered therapies, particularly in cardiovascular disease, rare disorders and obesity‑related conditions. His ongoing focus on unmet medical needs ensures that, while the organization reshapes its technology leadership, the medical and clinical vision remains firmly anchored in delivering tangible health outcomes.
Strategic Emphasis on Convergent Innovation
The collective leadership changes are designed to deepen Amgen’s commitment to convergent innovation—the deliberate fusion of biology, data science and advanced technologies such as artificial intelligence. By positioning AI and data expertise at the highest levels of R&D (Bradner) and technology operations (Bruich), while simultaneously aligning commercial and policy functions (Gordon) to accelerate adoption, Amgen seeks to shorten discovery timelines, improve clinical trial efficiency and enhance post‑market patient engagement. The approach reflects a broader industry shift toward integrating computational biology with traditional wet‑lab science to generate more precise, effective therapies.
Amgen’s Innovation Legacy and Market Standing
The release reiterates Amgen’s long‑standing reputation as an innovator, noting that the company helped establish the biotechnology industry more than 45 years ago at its Thousand Oaks headquarters. Today, Amgen remains a component of the Dow Jones Industrial Average® and the Nasdaq‑100 Index®, underscoring its status among the largest and most innovative non‑financial firms. Its pipeline spans cancer, inflammatory conditions, rare diseases, heart disease and obesity, with a stated goal of leveraging human genetic data and technology to push beyond current therapeutic limits. Recognition from Fast Company and Forbes further validates its workplace culture and inventive output.
Forward‑Looking Statements and Risk Disclosures
As required by SEC regulations, the press release includes a comprehensive forward‑looking‑statement section. It cautions that actual results may differ materially from projections due to factors such as market acceptance of new products, competitive pressures (including biosimilars), manufacturing constraints, regulatory developments, geopolitical influences, pricing and reimbursement pressures, litigation risks, intellectual‑property challenges, supply‑chain vulnerabilities, and macro‑economic conditions. The disclosure also notes that collaborations, acquisitions and strategic initiatives may not yield anticipated benefits, and that cybersecurity or data‑breach events could impair operations. These standard qualifications remind investors that while the leadership changes signal strategic optimism, numerous uncertainties remain.
Contact Information and Sources
For media inquiries, Elissa Snook can be reached at 609‑251‑1407; investor relations questions should be directed to Casey Capparelli at 805‑447‑1746. The release is sourced directly from Amgen and dated April 22, 2026, providing a transparent point of reference for journalists, analysts and stakeholders seeking further detail on the announced organizational evolution.